The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the ...

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

DexCom's stock is fairly valued despite positive Q4 2024 results, with muted enthusiasm from Wall Street today. Click here to ...

The Integrated Benefits Institute (IBI) today unveiled a report on employers' challenges in incorporating high-cost therapies ...

Trump’s executive orders included overhauls to U.S. trade policy and declaring a national emergency at the southern border.

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity.

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On ...

UnitedHealth's CEO acknowledged discontent with the health care system, but quickly shifted the blame elsewhere.

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

His time in service has informed his key values: commitment, tirelessness, perfectionism, and discipline. When he’s not ...

Fourth-quarter earnings at JPMorgan Chase, Wells Fargo, Goldman Sachs, and Citigroup beat analysts’ estimates.